Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC.
Aged
Carcinoma, Hepatocellular
/ complications
Cohort Studies
Disease-Free Survival
Female
Humans
Liver
/ metabolism
Liver Cirrhosis
/ complications
Liver Neoplasms
/ complications
Male
Middle Aged
Proportional Hazards Models
Risk Factors
Severity of Illness Index
Vitamin D
/ metabolism
Vitamin D Deficiency
/ complications
Cirrhosis
hepatocellular carcinoma
mortality
risk factors
vitamin D deficiency
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
10
09
2018
revised:
08
10
2018
accepted:
12
10
2018
entrez:
28
12
2018
pubmed:
28
12
2018
medline:
5
4
2019
Statut:
ppublish
Résumé
The aim of this study was to investigate the association between vitamin D deficiency (<10 mg/ml) and mortality in patients with and without hepatocellular carcinoma (HCC) in a cohort of patients with liver cirrhosis. A prospective study was conducted among 345 patients with liver cirrhosis. At enrolment, 46 (13.3%) patients had HCC. Severe vitamin D deficiency was associated with mortality (p<0.01). At the survival analysis, alpha-fetoprotein >10 ng/ml (p=0.003), vitamin D deficiency (p<0.001), a Model for End-Stage Liver Disease score ≥15 (p<0.001), Child-Pugh class B and C (versus A) (p<0.001) and the presence of active HCC (p<0.001) were strongly associated with death. At the multivariate Cox regression analysis, only Child-Pugh class B and C (versus A) and vitamin D deficiency were found to be significantly associated with death during the follow-up period (p<0.001 and p=0.006, respectively). Vitamin D deficiency is common in patients with HCC, it is associated with active HCC and it negatively affects the overall survival of patients with cirrhosis.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to investigate the association between vitamin D deficiency (<10 mg/ml) and mortality in patients with and without hepatocellular carcinoma (HCC) in a cohort of patients with liver cirrhosis.
MATERIALS AND METHODS
METHODS
A prospective study was conducted among 345 patients with liver cirrhosis.
RESULTS
RESULTS
At enrolment, 46 (13.3%) patients had HCC. Severe vitamin D deficiency was associated with mortality (p<0.01). At the survival analysis, alpha-fetoprotein >10 ng/ml (p=0.003), vitamin D deficiency (p<0.001), a Model for End-Stage Liver Disease score ≥15 (p<0.001), Child-Pugh class B and C (versus A) (p<0.001) and the presence of active HCC (p<0.001) were strongly associated with death. At the multivariate Cox regression analysis, only Child-Pugh class B and C (versus A) and vitamin D deficiency were found to be significantly associated with death during the follow-up period (p<0.001 and p=0.006, respectively).
CONCLUSION
CONCLUSIONS
Vitamin D deficiency is common in patients with HCC, it is associated with active HCC and it negatively affects the overall survival of patients with cirrhosis.
Identifiants
pubmed: 30587620
pii: 33/1/177
doi: 10.21873/invivo.11456
pmc: PMC6364065
doi:
Substances chimiques
Vitamin D
1406-16-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
177-182Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Nat Rev Cancer. 2003 Aug;3(8):601-14
pubmed: 12894248
J Interferon Cytokine Res. 2005 May;25(5):283-5
pubmed: 15871666
Hepatology. 2005 Aug;42(2):282-92
pubmed: 15986415
Oncology. 2006;70(6):447-57
pubmed: 17237620
Clin Gastroenterol Hepatol. 2007 Aug;5(8):938-45, 945.e1-4
pubmed: 17509946
Nat Rev Cancer. 2007 Sep;7(9):684-700
pubmed: 17721433
Acta Diabetol. 2007 Sep;44(3):167-9
pubmed: 17721757
Ann Epidemiol. 2009 Feb;19(2):73-8
pubmed: 18329892
J Hepatol. 2008 May;48(5):835-47
pubmed: 18334275
Cancer Res. 2009 Feb 1;69(3):967-75
pubmed: 19141646
Curr Osteoporos Rep. 2009 Jul;7(2):58-63
pubmed: 19631030
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2933-41
pubmed: 19861511
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Clin Liver Dis. 2011 May;15(2):223-43, vii-x
pubmed: 21689610
J Gastrointest Cancer. 2013 Dec;44(4):481-5
pubmed: 23925636
Hepat Mon. 2013 May 08;13(5):e8352
pubmed: 23967022
Hepatology. 2014 Oct;60(4):1222-30
pubmed: 24644045
Infez Med. 2014 Mar;22(1):11-8
pubmed: 24651085
Future Oncol. 2014 May;10(7):1129-32
pubmed: 24947253
Dig Liver Dis. 2014 Sep;46(9):826-32
pubmed: 24986781
J Steroid Biochem Mol Biol. 2016 Jan;155(Pt B):252-6
pubmed: 25864623
Cancer. 2015 Nov 1;121(21):3818-25
pubmed: 26178294
Nutrients. 2015 Sep 24;7(10):8251-60
pubmed: 26404359
Expert Opin Drug Discov. 2015 Dec;10(12):1363-77
pubmed: 26563720
Dig Dis Sci. 2016 Feb;61(2):636-45
pubmed: 26703125
Vitam Horm. 2016;100:395-431
pubmed: 26827961
Front Physiol. 2016 Oct 18;7:451
pubmed: 27803671
Gut. 2018 Aug;67(8):1536-1542
pubmed: 28320770
In Vivo. 2017 Jul-Aug;31(4):695-700
pubmed: 28652441
J Steroid Biochem Mol Biol. 2018 Mar;177:15-20
pubmed: 28746837
Cancer Invest. 2017 Sep 14;35(8):562-568
pubmed: 28799812
Int J Infect Dis. 2017 Oct;63:23-29
pubmed: 28804006
Eur J Intern Med. 2017 Dec;46:e45-e47
pubmed: 28918985
J Hepatol. 2018 Feb;68(2):326-334
pubmed: 29122695
Transl Gastroenterol Hepatol. 2017 Dec 06;2:101
pubmed: 29264439
J Viral Hepat. 2018 Jun;25(6):623-630
pubmed: 29274197
BMC Infect Dis. 2018 May 16;18(1):223
pubmed: 29769038